INTRODUCTION
n-3 and n-6 VLC-PUFAs are not normally consumed in the human diet, and EPA and AA appear to be their major precursors, respectively, in a process mediated by the action of the ELongation Of Very Long-chain fatty acids elongase 4 (ELOVL4) enzyme ( Figure 1 In order to clarify the roles LC-PUFAs and VLC-PUFAs in retinal health and disease, we previously undertook a study of human donor eyes to determine whether or not abnormalities in lipid profiles are present in AMD eyes. We found that DHA and many VLC-PUFA levels are significantly lower in AMD eyes relative to age-matched controls and that n-3/n-6 ratios are significantly lower for both LC-PUFAs and VLC-PUFAs (27). Since ELOVL4 genetic variants are not associated with AMD risk (28), these findings suggested that a retinal deficiency of LC-PUFAs and VLC-PUFAs influenced by diet and/or a dietary imbalance of n-3/n-6 LC-PUFA ratios may be involved in AMD pathology, but our study was limited by the low number of AMD eyes (n=8) and lack of availability of biomarkers of dietary lipid intake. We now report follow-up studies showing that dietary intake of LC-PUFA and VLC-PUFA precursors clearly influence retinal lipid profiles in retina, and they confirm that AMD eyes have numerous abnormalities in these profiles.
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www.jlr.org Downloaded from 6 eicosanoate, methyl linolenate, methyl melissate, and Supelco-37 (a commercial mixture of FAMEs) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Matreya (Pleasant Gap, PA, USA). Silica gel, glass-encased, solid-phase extraction cartridges (500 mg/6 ml) were purchased from Sorbent Technology (Atlanta, GA, USA). The internal standards, tridecanoic acid and hentriacontanoic acid, were dissolved in nonane at concentrations of 1.0 mg/ml and 0.023 mg/ml, respectively.
Lipid extraction and purification of lipids with solid-phase extraction
Serum, RBCs, orbital adipose tissue, and retina punches, were extracted using the procedure previously adopted in our laboratory (30). The samples and internal standards (50 µg of tridecanoic acid and 1.15 µg of hentriacontanoic acid) were added in 2 ml stainless steel vials and then homogenized with 0.7 ml silica beads and 1 ml hexane-isopropanol (3:2 v: v) by a Mini Bead Beater-16 (BioSpec Products Inc., Bartlesville, Oklahoma, USA) and a Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA, USA). The homogenized samples were bath sonicated for 5 min in an ice water bath. After centrifugation at 10,000 rpm for 5 min, the extracted solution supernatant was transferred to a clean vial and then dried under a stream of nitrogen. The dried film was dissolved in 200 µl hexane, and 2 ml of 4% HCl in methanol was added. The tubes were flushed with argon and incubated at 80°C for 4 hr to form FAMEs (30) and then allowed to cool. The FAME mixture was extracted three times with 1 ml distilled water and 2 ml hexane. The hexane layers were combined and dried under nitrogen gas.
Silica gel, glass-encased, solid-phase extraction cartridges were subsequently used to clean the FAME extracts. The cartridge was activated with 6 ml of hexane before loading samples. The crude FAME extract was dissolved in 200 µl of hexane and loaded onto the activated cartridge. The cartridge was washed with 6 ml hexane, and the eluate was discarded. FAMEs were eluted from the cartridge with 5 ml hexane:ether (4:1), and the eluate was evaporated under nitrogen gas. The dry film was dissolved in 200 µl of hexane and centrifuged for 3 min at 14,000 rpm to remove particles prior to GC-MS analysis. 1 µl of sample was injected into the GC-MS instrument for LC-PUFAs analysis. For VLC-PUFAs analysis, the sample was dried with nitrogen again and re-dissolved in 20 μl of n-nonane, and 5 µl samples were injected into the GC-MS instrument. 
GC-MS Instrumentation and Chromatographic Conditions
The Thermo Trace GC-DSQ II system (ThermoFisher Scientific, Waltham, MA, USA) consists of an automatic sample injector (AS 3000), gas chromatograph (GC), single quadrupole mass detector, and an analytical workstation. The chromatographic separation was carried out with an Rxi-5MS coated 5% diphenyl/95% dimethyl polysiloxane capillary column (30 m × 0.25 mm i.d, 0.25 µm film thickness) (Restek, Bellefonte, PA, USA). Two methods (A and B) were used for detection and quantitation of LCPUFAs and VLC-PUFAs, respectively.
For LC-PUFA analyses, the following mass spectrometry conditions were used (Method A): 1 µl from a 200 µl sample was injected into the GC-MS using a splitless mode; the septum purge was on; and the injector temperature was set at 200°C. The column temperature was programmed as follows: initial temperature 60°C; 5 degree/min to 170°C; 1 degree/min to 180°C; 2 degree/min to 240°C; 4 degree/min to 290°C; and a hold at 290°C for 5 min. Transfer line temperature was 290°C. Helium was used as the carrier gas at a flow rate of 1.0 ml/min. Mass spectrometry conditions were as follows: electron ionization 
Genotyping
Genotyping was done using the TaqMan platform (Applied Biosystems, Grand Island, NY, USA). Amplification and genotype assignments were conducted using the 7900HT and SDS 2.4 software. The SNPs, rs381253 and rs10753929, used in this study were selected based upon their association with ELOVL4 and adiponectin receptor 1 (AdipoR1) as reported in earlier literature (32, 33).
Statistical Analyses
Statistical analyses were performed using analysis of variance (ANOVA), linear regressions, chi square tests, and t-tests on Prism software (GraphPad Software Inc., La Jolla, CA, USA). Data are represented as the mean ± SD. Significance is indicated by P value measurements, with P<0.05 considered significant.
RESULTS

Phase I Study
Forty-four normal patient samples were collected (average age ± SD = 71.4 ± 13.4 years), and their serum, RBCs, orbital fat, and retinal punches were analyzed using GC-MS techniques. We studied the correlations between the retinal lipid profile and those of serum, RBCs, and fat which are validated biomarkers of short-term (weeks), medium-term (months), and long-term dietary fat intake (years) (26, 34, 35, 36) ( Table 2 ). Individual key LC-PUFAs (EPA, DHA, and AA) in serum, RBCs, and fat generally showed significant positive correlations with corresponding levels in retinal lipids. We observed strong positive correlations between EPA levels in serum, RBCs, and fat with EPA levels in retina (all P<0.001), while retinal DHA levels correlate relatively weakly only with DHA levels of RBCs (P<0.05). The levels of the major n-6 fatty acid in retina, AA, were also in positive correlation with AA levels in serum and RBCs (P<0.001). Likewise, serum and RBC total LC-PUFAs positively correlated with retinal total LCPUFAs (P<0.001), but fat had a weaker negative correlation (P<0.05) ( Table 2 ).
Next, we examined various correlations with retinal VLC-PUFAs (Table 3) . RBC total LCPUFAs significantly correlated with retinal total VLC-PUFAs (P<0.01), but serum and fat did not.
However, not all LC-PUFAs are considered to be major precursors of retinal VLC-PUFAs (Figure 1 ), so we focused subsequent analyses on the following VLC-PUFA precursors: 18:3n-3, 18:4n-3, 20:4n-3, 20:5n-3, and 22:5n-3 for n-3 VLC-PUFAs and 18:2 n-6, 18:3n-6, 20:3n-6, 20:4n-6, and 22:4n-6 for n-6 VLC-PUFAs. Most notably, this sub-analysis specifically excludes DHA (22:6n-3) which is a common systemic lipid but is not considered a significant precursor for VLC-PUFAs (37). This improved correlations substantially. Total VLC-PUFA precursor levels in serum and RBCs were positively associated with total retinal VLC-PUFA levels in the retina (P<0.01 and P<0.001, respectively) ( Table 3 ).
When we separately analyzed the n-3 and n-6 series, many of these positive correlations persisted (P<0.001 for RBC n-3 and n-6 lipids and for serum n-6 lipids).
Most organisms do not interconvert lipids between the n-3 and n-6 series, so the n-3/n-6 ratios of various lipids are important to ascertain, especially since n-6 series lipids are generally pro-inflammatory, while the n-3 lipids are not. We found many strong and consistent correlations between serum, RBCs, and fat n-3/n-6 ratios in systemic LC-PUFAs and VLC-PUFA precursors with retinal LC-PUFAs, VLCPUFAs, and their precursors (Table 4 and Figures 2A and 2B) . We also noted that systemic EPA/AA ratios correlated well with retina EPA/AA ratios (P<0.001 for serum, RBCs, and fat), but DHA/AA ratios did not correlate significantly. In fact, the simple EPA/AA ratios in serum, RBCs, or fat were highly predictive biomarkers of n-3/n-6 ratios of retinal VLC-PUFAs (Table 4 and Figure 2C ).
When data from individual participants were examined, one of the 44 subjects was noted to be an outlier with unusually high levels of EPA and DHA in serum, RBCs, and fat ( Figure 3 ). Likewise, this donor's n-3/n-6 ratios were much higher than the others (Figure 2 ). When we contacted the subject's family, we learned that he had been consuming a high dose of fish oil (7 g/day) for at least 18 months prior to death. Excluding his data from statistical analysis did not change the statistical significance of any of our findings reported in Tables 2-4 , and his unusual systemic lipid levels and n-3/n-6 ratios corresponded well with elevated n-3 retinal VLC-PUFA levels and very high n-3/n-6 VLC-PUFA ratios (Figures 2, 3 , and 4).
Phase II Study
In the second phase of this project, we examined an independently collected cohort of AMD (n=15) and control (n=21) subjects who had donated eyes and serum (Table 1) . We sampled normal appearing peripheral retina for these analyses in order to rule out macular fibrosis, atrophy, or other advanced AMD pathology as an explanation for the differences between AMD and control eyes. This time, serum LC-PUFAs and VLC-PUFA precursors were significantly associated with retina VLC-PUFA levels for controls, while the associations had similar trends in AMD donors, but they were not significant. Serum LC-PUFAs and serum VLC-PUFA precursors were significantly correlated with retinal VLC-PUFAs for controls (P<0.05), and a similar trend was seen for the AMD subjects, but it did not reach statistical significance (Table 5 ). Serum n-3/n-6 LC-PUFA ratios significantly correlated with retinal n-3/n-6 VLC-PUFA ratios for AMD and control eyes (P values ranging from 0.01 to 0.006), and similar trends were also seen when comparing serum n-3/n-6 VLC-PUFA precursor ratios versus retinal n-3/n-6 VLC-PUFA ratios, but statistical significance was reached only when AMD and control data were combined (P=0.04). Serum EPA/AA ratios were in significant positive correlation with the retinal n-3/n-6 VLC-PUFA ratios in controls but not AMD subjects.
Retinal VLC-PUFA levels in AMD eyes (0.64% ± 0.10) were significantly lower than those found in age matched control eyes (1.11% ± 0.21) ( Figure 5A ). We also observed that n-3/n-6 VLC-PUFA ratios were significantly lower in AMD eyes (1.29 ± 0.12), as compared to those found in agematched control eyes (1.69 ± 0.18) ( Figure 5B ). Serum n-3/n-6 LC-PUFA and VLC-PUFA precursor ratios were significantly lower (P<0.05) in AMD patients (0.35 ± 0.02, 0.18 ± 0.01) when compared to those of age-matched controls (0.45 ± 0.04, 0.23 ± 0.02) ( Figure 6 ). Likewise, serum EPA/AA ratios in AMD subjects (0.072 ± 0.006) were lower than age-matched controls (0.102 ± 0.011), but this trend was not statistically significant (P=0.09).
DNA was also available for these Phase II subjects, and we examined whether or not variants in ELOVL4 and AdipoR1 (a regulator of retinal VLC-PUFA levels (38)) have any influence on AMD risk or lipid profiles in this cohort, but we found no significant relationships, nor did we find any statistically significant influences for AMD grade (Table 1, In the first phase of this study, we prospectively collected serum, RBCs, orbital fat, and retinal tissue from donors with no known eye diseases to ascertain whether or not these systemic biomarkers of dietary lipid consumption truly represent what is going on at the tissue level. We used a high sensitivity GC-MS analytical protocol developed in our laboratory (30) that requires minimal amounts of valuable retinal tissue; typically a single 4-6 mm punch is sufficient. Our GC-MS method readily allows for the distinction between n-3 and n-6 LC-PUFAs and VLC-PUFAs, which is in contrast to LC-MS methods (8, 39) which do not permit distinction between these two important classes of lipids, one of which is generally anti-inflammatory and associated epidemiologically with decreased AMD risk (n-3 series) and one of which is pro-inflammatory and associated with increased AMD risk (n-6 series) (40, 41). Table 2 demonstrate that serum and RBC lipid biomarkers are highly predictive of retinal lipid composition for total LC-PUFAs, EPA, and AA. Orbital fat is associated only with retinal EPA levels. On the other hand, retinal DHA levels have much lower associations with systemic lipid biomarkers, consistent with a more active and regulated uptake of DHA into the human retina relative to other LC-PUFAs. We examined whether LC-PUFA biomarkers correlate with retinal VLC-PUFAs, and we found that only RBCs were significantly associated (Table 3) . When we excluded systemic DHA, which is not a major precursor of VLC-PUFAs, we could improve the correlations for RBCs and serum substantially, especially with regard to the n-3 series. Finally, we looked at n-3/n-6 ratios systemically and in the retina and found strong and consistent correlations for all three biomarkers as long as DHA was excluded (Table 4 ). In fact, just a simple EPA/AA ratio could accurately reflect the n-3/n-6 ratio of the VLC-PUFAs in the retina.
Our results depicted in
The hypothesis that diet can profoundly influence retinal lipid composition was supported in dramatic fashion by an outlier in our group of 44 donors. As shown in Figures 2, 3 , and 4, his n-3/n-6 and EPA/AA ratios were several times higher systemically and in the VLC-PUFAs of the retina relative to all of the other donors. Although dietary histories were not part of this study, it is clear that his daily consumption of 7 grams per day of fish oil is expected to be more than 10 times higher than what anyone would consume from diet alone and is seven times higher than the dose tested in AREDS2. The outlier serum showed an increase of EPA over AA (Figure 3) , thereby increasing the serum n-3/n-6 LC-PUFA ratio to 6 times higher than normal human serum. Simultaneously, the n-3/n-6 VLC-PUFA ratio in retina of the outlier patient was also elevated in comparison to normal human retina by 6 times, consistent with a strong effect of diet on n-3/n-6 VLC-PUFA ratios in retina.
In the second phase study, we tested control and AMD samples from the Utah Center for Translational Medicine Donor Eye Repository, an independent cohort of donors with rigorously characterized clinical histories. As we have seen before, the AMD donors have significantly lower retinal n-3 VLC-PUFAs (50%), VLC-PUFA levels (40%) and n-3/n-6 VLC-PUFA ratios than age-matched controls ( Figure 5 ), and serum LC-PUFA, VLC-PUFA precursor, EPA/AA, and n-3/n-6 LC-PUFA ratios were likewise lower relative to age-matched controls ( Figure 6 ). Table 5 shows that for control donors, by guest, on September 8, 2017
www.jlr.org Downloaded from serum n-3/n-6 ratios of LC-PUFA, VLC-PUFA precursors, and EPA/AA generally predicted retinal VLC-PUFA ratios, and for AMD donors similar trends were seen. Table 3 indicates that RBC lipids were better biomarkers than serum for retinal VLC-PUFAs in the Phase I study, but unfortunately only serum was available for the Phase II study. We are therefore uncertain whether the significant associations of systemic lipid status with retinal VLC-PUFAs in controls versus the non-significant associations in AMD subjects seen in Table 5 are simply reflections of serum biomarker variability or if there are true differences in retina lipid uptake and metabolism between normal and AMD eyes. We did explore the possibility that variants in ELOVL4 (the key enzyme in VLC-PUFA synthesis) (20) or AdipoR1 (a regulator of VLC-PUFA synthesis associated with AMD risk) (38) could explain the difference between AMD and control eyes, but we found no evidence for their involvement (Table 1 ). In agreement with our results, others could not attain statistically significant correlation between ELOVL4 gene and macular degeneration (28, 42) . The association of AdipoR1 gene expression with AMD risk in our cohort was insignificant (P>0.1), which is in contrast with a recently published Finnish population study (33). In fact, the risk allele of AdipoR1 (CT) was found in only one of our 15 AMD subjects.
Few other studies have examined relationships between biomarkers of systemic lipid status and adult human retinal lipid composition. In 2008, a research group from France reported a negative correlation of retinal DHA with orbital fat DHA (8), which is in agreement with our present results. A follow up study by this same group examined RBCs and retinal lipids from nine elderly donors and found that gas chromatography with flame ionization detection yielded significant correlations for only AA and n-3/n-6 ratios (43). Additional positive and negative correlations between RBC lipids with retinal LCPUFAs and VLC-PUFAs were discernable when they used liquid chromatography coupled to an electrospray ionization source-mass spectrometer (LC-ESI-MS), but this analytical technique is unable to distinguish between n-3 and n-6 fatty acids.
The results reported here have several important implications. First, they confirm our prior findings that VLC-PUFA levels and n-3/n-6 ratios are lower in AMD eyes (27). This suggests that further studies to understand the physiology of these unusual retinal lipids are warranted. Knockdown of VLC-PUFA levels in mice produces abnormalities only in extreme conditions (i.e. 90% knockdown) (24), but it must be noted that humans have much lower basal levels of retinal VLC-PUFAs than mice (30), so the lower levels that we observed in AMD eyes may indeed induce physiological and structural disruption in the photoreceptors. Second, our results emphasize the importance of assessing n-3/n-6 ratios systemically and in the retina when studying the potential role of dietary and supplemental lipids in modifying AMD risk, as systemic n-3/n-6 ratios show tight and consistent correlations with retinal health and are readily measured with GC-MS. Third, these data demonstrate that biomarkers of systemic lipid status accurately reflect lipid status in the retina, especially with regard to VLC-PUFAs.
Future observational and interventional projects studying nutritional benefits of n-3 fatty acids should include easily obtained biomarkers of short-term and medium-term lipid intake (serum and RBCs, respectively) to account for variability of background diet, intestinal absorption efficiency, and participant compliance. Diet plays an important role in altering the levels and ratios of n-3/n-6 LC-PUFAs in serum which in turn influence the n-3/n-6 LC-PUFA and VLC-PUFA ratios and levels in retina with possible beneficial effects on macular physiology and protection against degeneration. Our results clarify the biological mechanisms underlying epidemiological studies which have shown that diets rich in n-3 fatty acids are protective against AMD. 
